Pain management in multiple myeloma

Expert Review of Anticancer Therapy

Volumn 10, Issue 3, 2010, Pages 415-425

  Niscola, Pasquale ^a   Scaramucci, Laura ^a   Romani, Claudio ^b   Giovannini, Marco ^c   Tendas, Andrea ^a   Brunetti, Gregorio ^d   Cartoni, Claudio ^d   Palumbo, Roberto ^a   Vischini, Gisella ^a   Siniscalchi, Agostina ^a   Fabritiis, Paolo De ^a   Caravita, Tommaso ^a  

^a S EUGENIO HOSPITAL   (Italy)

^b Department of Haematology   (Italy)

^c Frosinone Hospital   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Analgesics; Bone disease; Chemotherapy; Multiple myeloma; Opioids; Pain; Radiotherapy; Spine vertebroplastic

Indexed keywords

AMITRIPTYLINE; BACLOFEN; BORTEZOMIB; BUPRENORPHINE; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; FENTANYL; FLUORODEOXYGLUCOSE; GABAPENTIN; HYDROMORPHONE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; METHADONE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PALIFERMIN; PAMIDRONIC ACID; PARACETAMOL; PREGABALIN; THALIDOMIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLEDRONIC ACID;

ABSCESS; ADJUVANT THERAPY; ANALGESIA; BACTERIAL INFECTION; BEDTIME DOSAGE; BIOMECHANICS; BONE DISEASE; BONE MARROW BIOPSY; BONE METASTASIS; BONE PAIN; CANCER PAIN; CELLULITIS; CHRONIC PAIN; COMPUTER ASSISTED TOMOGRAPHY; COPING BEHAVIOR; CRYOTHERAPY; DENTAL CARE; DRUG DOSE TITRATION; DRUG MEGADOSE; HEADACHE; HUMAN; KIDNEY FAILURE; MUCOSA INFLAMMATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE MYELOMA; MUSCLE ATROPHY; NERVE ROOT COMPRESSION; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC EQUIPMENT; OSTEOLYSIS; PAIN ASSESSMENT; PAIN PARAMETERS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT CONTROLLED ANALGESIA; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PLEURISY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; POSTDURAL PUNCTURE HEADACHE; RADIOFREQUENCY ABLATION; RELAXATION TRAINING; REVIEW; SCINTIGRAPHY; SKELETON RADIOGRAPHY; SPINAL CORD COMPRESSION; TONGUE ULCER; VIRUS REACTIVATION; VISUAL ANALOG SCALE; WHOLE BODY MRI;

ADMINISTRATION, ORAL; ANALGESICS; HUMANS; MULTIPLE MYELOMA; PAIN; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; QUALITY OF LIFE; WORLD HEALTH ORGANIZATION;

EID: 77949461451     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.10.5     Document Type: Review

References (94)

1. Niscola P, Arcuri E, Giovannini M et al. Pain syndromes in haematological malignancies: an overview. Hematol. J. 5(4), 293-303 (2004).
2. Poulos AR, Gertz MA, Pankratz VS, Post-White J. Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol. Nurs. Forum 28(7), 1163-1171 (2001).
3. Lennert H. Pain therapy in multiple myeloma - clinical experience from an observational study. The Pain Clinic 18(2)6, 131-136 (2006).
4. Smith A, Wisloff F, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br. J. Haematol. 132(4), 410-451 (2006).
5. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin. Proc. 50(1), 29-40 (1975).
6. Zappasodi P, Corso A, Klersy C et al. Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience. Eur. J. Cancer 42(3), 396-402 (2006).
7. Niscola P, Romani C, Cartoni C et al. Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk. Res. 32(1), 197-198 (2008).
8. Niscola P, Cartoni C, Romani C et al. Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann. Hematol. 86(9), 671-676 (2007).
9. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 23(3), 435-441 (2009).
10. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract. Res. Clin. Haematol. 18(4), 673-688 (2005).
11. Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol. Oncol. 26(2), 55-65 (2008).
12. Suzuki M, Ohashi K, Sakamaki H. Immunoglobulin D plasmacytoma carrying aberrant expression of CD33 associated with aggressive visceral involvement. Haematologica 86(8), 895 (2001).
13. Niscola P, Scaramucci L, Morabito F et al. Pleural effusion by malignant plasma cells in advanced multiple myeloma: report of three cases with a brief overview. Haematologica 7(4), 516-519 (2004).
14. Ochiai N, Shimazaki C, Okano A et al. Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma. Leuk. Lymphoma 43(3), 641-643 (2002).
15. Desikan R, Barlogie B, Sethi R et al. Infection 2004 - an underappreciated cause of bone pain in multiple myeloma. Br. J. Haematol. 120(6), 1047-1050 (2003).
16. Niscola P, Perrotti AP, del Poeta G et al. Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes 14(2), 45-47 (2007).
17. Leena M, Ville V, Veli-Jukka A. Visceral varicella zoster virus infection after stem cell transplantation: a possible cause of severe abdominal pain. Scand J. Gastroenterol. 41(2), 242-244 (2006).
18. Coutaux A, Salomon L, Rosenheim M et al. Care related pain in hospitalized patients: a cross-sectional study. Eur. J. Pain 12(1), 3-8 (2008).
19. Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic malignancies: an overview. Haematologica 92(2), 222-231 (2007).
20. Niscola P, Romani C, Scaramucci L et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant. 41(9), 757-764 (2008).
21. Smith LC, Bertolotti P, Curran K, Jenkins B. IMF Nurse Leadership Board. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF nurse leadership board. Clin. J. Oncol. Nurs. 12(3 Suppl.), 37-52 (2008).
22. Siniscalchi A, Tendas A, Ales M et al. Bortezomib-related colon mucositis in a multiple myeloma patient. Support Care Cancer 17(4), 325-327 (2009).
23. Srinivasan D, Shetty S, Ashworth D, Grew N, Millar B. Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br. Dent. J. 203(2), 91-92 (2007).
24. Badros A, Terpos E, Katodritou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol. 26(36), 5904-5909(2008).
25. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20(1), 117-120 (2009).
26. Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 27(32), 5356-5362 (2009).
27. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44(9), 857-869 (2008).
28. Treister NS, Richardson P, Schlossman R, Miller K, Woo SB. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 105(6), E1-E4 (2008).
29. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J. Clin. Oncol. 24(27), 4507-4514 (2006).
30. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J. Peripher. Nerv. Syst. 13(4), 275-282 (2008).
31. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J. Support. Oncol. 1(3), 194-205 (2003).
32. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
33. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J. Pain 8(4), 296-306 (2007).
34. Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24(19), 3113-3120 (2006).
35. El-Cheikh J, Stoppa AM, Bouabdallah R et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin. Lymphoma Myeloma 8(3), 146-152 (2008).
36. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5), 1593-1599 (2008).
37. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol. 63(5), 761-767 (2009).
38. Ravaglia S, Corso A, Piccolo G et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin. Neurophysiol. 119(11), 2507-2512 (2008).
39. Woolf CJ. American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med. 140(6), 441-451 (2004).
40. Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European association for palliative care. Cancer 94(3), 832-839 (2002).
41. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain 10(9), 895-926 (2009).
42. Davis MP, Walsh D. Cancer pain: how to measure the fifth vital sign. Cleve. Clin. J. Med. 71(8), 625-632 (2004).
43. Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 35(9), 632-640 (2006).
44. Dinter DJ, Neff WK, Klaus J et al. Comparison of whole-body MR imaging and conventional x-ray examination in patients with multiple myeloma and implications for therapy. Ann. Hematol. 88(5), 457-464 (2009).
45. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur. J. Radiol. 70(3), 401-408 (2009).
46. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 25(17), 2464-2472 (2007).
47. Musto P, Petrucci MT, Bringhen S et al. A multicenter randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Eur. J. Radiol. 113(7), 1588-1595 (2008).
48. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5), 820-831 (2007).
49. Lilleby K, Garcia P, Gooley T et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 37(11), 1031-1035 (2006).
50. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351(25), 2590-2598 (2004).
51. Tariman JD, Love G, McCullagh E, Sandifer S; IMF Nurse Leadership Board. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin. J. Oncol. Nurs. 12(3 Suppl.), 29-36 (2008).
52. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr. Pain Headache Rep. 10(4), 279-287 (2006).
53. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer 44(11), 1507-1515 (2008).
54. Niscola P, Scaramucci L, Romani C et al. Opioids in pain management of blood-related malignancies. Ann. Hematol. 85(8), 489-501 (2006).
55. Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol. 176(11), 506-512 (2000).
56. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of randomised trials. Clin. Oncol. (R. Coll. Radiol.) 15(6), 345-352 (2003).
57. van den Hout WB, van der Linden YM, Steenland E et al. Single versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J. Natl Cancer Inst. 95(3), 222-229 (2003).
58. Rades D, Hoskin PJ, Stalpers LJ et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int. J. Radiat. Oncol. Biol. Phys. 64(5), 1452-1457 (2006).
59. Munk PL, Rashid F, Heran MK et al. Combined cementoplasty and radiofrequency ablation in the treatment of painful neoplastic lesions of bone. J. Vasc. Interv. Radiol. 20(7), 903-911 (2009).
60. Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 15(3), 339-342 (2007).
61. Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin. Investig. Drugs 17(9), 1379-1387 (2008).
62. Buchbinder R, Osborne RH, Ebeling PR et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N. Engl. J. Med. 361(6), 557-568 (2009).
63. Masala S, Anselmetti GC, Marcia S, Massari F, Manca A, Simonetti G. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J. Spinal Disord. Tech. 21(5), 344-348 (2008).
64. Astolfi S, Scaramuzzo L, Logroscino CA. A minimally invasive surgical treatment possibility of osteolytic vertebral collapse in multiple myeloma. Eur. Spine J. 18(Suppl. 1), 115-121 (2009).
65. Tran Thang NN, Abdo G, Martin JB, Seium-Neberay Y et al. Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. Support Care Cancer 16(8), 891-896 (2008).
66. World Health Organization. Cancer Pain Relief. World Health Organization, Geneva, Switzerland (1986).
67. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol. 22(5), 467-474 (2009).
68. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 326, 748-750 (2003).
69. Cavazzini F. The combination acetominophen/tramadol in hematological daily practice. Minerva Med. 99(6), 631-641 (2008).
70. Cartoni C, Brunetti GA, Niscola P, Alfieri PL, Delia GM, Foà R. Pain management of bortezomib-induced neuropathy with oral controlled-release oxycodone. Haematologica 94(Suppl. 2), 49 (2009).
71. Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with breakthrough pain. Expert Opin. Pharmacother. 10(6), 947-953 (2009).
72. Stanos SP. Topical agents for the management of musculoskeletal pain. J. Pain Symptom Manage. 33(3), 342-355 (2007).
73. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J. Physiol. Pharmacol. 59(Suppl 2), 117-133 (2008).
74. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin. J. Pain 18(4 Suppl.), S3-S13 (2002).
75. Hanks GW, de Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations Expert Working Group of the Research Network of the European Association for Palliative Care. Br. J. Cancer 84, 587-593 (2001).
76. Swarm R, Anghelescu DL, Benedetti C et al. National comprehensive cancer network (NCCN). Adult cancer pain. J. Natl Compr. Canc. Netw. 5(8), 726-751 (2007).
77. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 43(13), 879-923 (2004).
78. Mercadante S. Methadone in cancer pain. Eur. J. Pain 1(2), 77-83 (1997).
79. Kress HG, Von der Laage D, Hoerauf KH et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared with standard opioid treatment in cancer pain. J. Pain Symptom Manage. 36(3), 268-279 (2008).
80. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol. 5(7), 327-334 (2007).
81. Pergolizzi JV, Mercadante S, Echaburu AV et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr. Med. Res. Opin. 25(6), 1517-1528 (2009).
82. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer 17(6), 715-718 (2009).
83. Cherny N, Ripamonti C, Pereira J et al. Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. 19(9), 2542-2554(2001).
84. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am. J. Med. 122(10 Suppl.), S22-S32 (2009).
85. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol. 22(5), 467-474 (2009).
86. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 9(2), 36 (2007).
87. Mercadante S, Arcuri E. Opioids and renal function. J. Pain 5(1), 2-19 (2004).
88. Niscola P, Scaramucci L, Vischini G et al. The use of major analgesics in patients with renal dysfunction. Curr. Drug Targets (2010) (In press).
89. Cassileth B, Trevisan C, Gubili J. Complementary therapies for cancer pain. Curr. Pain Headache Rep. 11(4), 265-269 (2007).
90. Jones LW, Courneya KS, Vallance JK et al. Understanding the determinants of exercise intentions in multiple myeloma cancer survivors: an application of the theory of planned behavior. Cancer Nurs. 29(3), 167-175 (2006).
91. Stanos SP, McLean J, Rader L. Physical medicine rehabilitation approach to pain. Med. Clin. North Am. 91(1), 57-95 (2007).
92. Falco P, Cavallo F, Larocca A et al. Lenalidomide and its role in the management of multiple myeloma. Expert Rev. Anticancer. Ther. 8(6), 865-874 (2008).
93. Laubach JP, Mitsiades CS, Mahindra A et al. Novel therapies in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw. 7(9), 947-960 (2009).
94. Roodman GD. Novel targets for myeloma bone disease. Expert Opin. Ther. Targets 12(11), 1377-1387 (2008).